J Cancer 2016; 7(8):1010-1019. doi:10.7150/jca.14425
An Investigation on a Novel Anti-tumor Fusion Peptide of FSH33-53-IIKK
1. Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China.
2. School of Pharmaceutical Science, Zhengzhou University, Zhengzhou 450000, China.
3. The First School of Clinical Medicine, Nanjing Medical University, Nanjing 210029, China.
4. Department of Medical Physics, University of Wisconsin, Madison, WI 53705, USA.
5. Department of Nuclear Medicine, Hua Shan Hospital, Fudan University, Shanghai 200040, China.
A novel fusion peptide FSH33-53-IIKK was designed and expected to combine the follicle stimulating hormone receptor (FSHR) targeting and tumor toxicity. In vitro and in vivo study showed the anti-tumor activity of FSH33-53-IIKK was enhanced compared to that of IIKK only. FSH33-53-IIKK could inhibit the growth of tumor via apoptosis and autophagy pathways. In summary, combining the tumor marker-target peptide and anti-tumor peptide together may be an efficient way to search for better anti-tumor candidates.
Keywords: FSH33-53-IIKK, Fusion peptide, FSHR, Anti-tumor, Apoptosis, Autophagy
Yang R, Liu P, Pan D, zhang P, Bai Z, Xu Y, Wang L, Yan J, Yan Y, Liu X, Yang M. An Investigation on a Novel Anti-tumor Fusion Peptide of FSH33-53-IIKK. J Cancer 2016; 7(8):1010-1019. doi:10.7150/jca.14425. Available from http://www.jcancer.org/v07p1010.htm